Jump to content

User:Wpcrosson/sandbox

From Wikipedia, the free encyclopedia

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26]

  1. ^ Kalluri, Raghu; Weinberg, Robert (June 2009). "The basics of epithelial-mesenchymal transition". The Journal of Clinical Investigation. 119 (6): 1420–1428. doi:10.1172/JCI39104.
  2. ^ Ruben, Bill; Christofori, Gerhard (June 2015). "The relevance of EMT in breast cancer metastasis: Correlation or causality?". The Biochemical Basis of Life. 589 (14): 1577–1587. doi:10.1016/j.febslet.2015.05.002.
  3. ^ Nickel, Annina; Stadler, Sonja (January 2015). "Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of breast cancer cells". Translational Research. 165 (1): 126–142. doi:10.1016/j.trsl.2014.04.001.
  4. ^ Thiery, Jean (June 2002). "Epithelial–mesenchymal transitions in tumour progression". Nature Reviews Cancer. 2: 442–454. doi:10.1038/nrc822.
  5. ^ Cho, Kyung; et, al. (2015). "Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer cell aggressiveness through downregulating HIF-1α expression". Biomed Central Cancer. 15 (829). doi:10.1186/s12885-015-1864-y.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  6. ^ Pomp, Victoria; et, al. "Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer". Breast Cancer Research Treatments. 154: 45–55. doi:10.1007/s10549-015-3598-6.
  7. ^ Veevers-Lowe, Jennifer; et, al. (2011). "Mesenchymal stem cell migration is regulated by fibronectin through a5b1-integrin-mediated activation of PDGFR-b and potentiation of growth factor signals". Journal of Cell Science. 124: 1288–1300. doi:10.1242/jcs.076935.
  8. ^ Sorlie, T; et, al. (1998). "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications". Proceedings of the National Academy of Sciences of the United States of America. 19: 10869–10874.
  9. ^ Yang, Sherry; et, al (April 2016). "New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer". Cancer Treatment Reviews. 45: 87–96. doi:10.1016/j.ctrv.2016.03.004.
  10. ^ Yadav, Budhi; et, al (December 10, 2015). "Biomarkers in triple negative breast cancer: A review". World Journal of Clinical Oncology. 6 (6): 252–263. doi:10.5306/wjco.v6.i6.252.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  11. ^ Banerjee, Kasturi; Resat, Haluk (2015). "Constitutive activation of STAT3 in breast cancercells: A review". International Journal of Cancer. 138: 2570–2578. doi:10.1002/ijc.29923.
  12. ^ Y, Shimono; et, al (Dec 25, 2015). "MicroRNA Regulation of Human Breast Cancer Stem Cells". Journal of Clinical Medicine. 5 (1). doi:10.3390/jcm5010002.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  13. ^ Hemmatzadeh, Maryam (March 2016). "The role of oncomirs in the pathogenesis and treatment of breast cancer". Biomedicine and Pharmacology. 78: 129–139. doi:10.1016/j.biopha.2016.01.026.
  14. ^ M, Kai; et, al (June 2015). "Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin". Breast Cancer Research and Treatment. 151 (2): 281–294. doi:10.1007/s10549-015-3376-5.
  15. ^ F, Puglisi; et, al (Feb 2016). "Current challenges in HER2-positive breast cancer". Critical reviews in Oncology/Hematology. 98: 211–221. doi:10.1016/j.critrevonc.2015.10.016.
  16. ^ H.E., Barratt; et, al (April 2016). "Tamoxifen promotes differentiation of oligodendrocyte progenitors in vitro". Neuroscience. 319: 146–154. doi:10.1016/j.neuroscience.2016.01.026.
  17. ^ Redfern, Andrew; et, al (2016). "Hormone receptor positive, HER2 negative metastatic breastcancer: Future treatment landscape". Journal of Clinical Oncology. 12: 19–31. doi:10.1111/ajco.12492.
  18. ^ Saldanha, Gerald; et, al (2016). "microRNA-10b is a prognostic biomarker for melanoma". Modern Pathology. 29: 112–121.
  19. ^ Darst, Seth (2004). "New inhibitors targeting bacterial RNA polymerase". Trends in Biochemical Sciences. 29 (4): 159–162.
  20. ^ Darst, Seth; Wilson, Kelly-Ann (2003). "Structure of Microcin J25, a Peptide Inhibitor of Bacterial RNA Polymerase, is a Lassoed Tail". JACS Articles. 125 (41): 12475–12483.
  21. ^ Mukhopadhyay, Jayanta; Ebright, Richard (2004). "Antibacterial Peptide Microcin J25 Inhibits Transcription by Binding within and Obstructing the RNA Polymerase Secondary Channel". Molecular Cell. 14 (6): 739–751.
  22. ^ Morero, Roberto; Niklison-Chirou, Maria (2010). "Microcin J25 triggers cytochrome c release through irreversible damage of mitochondrial proteins and lipids". The International Journal of Biochemistry & Cell Biology. 42 (2): 273–281.
  23. ^ Ero-Trolliver, Isi; Hudson, Billy; Bhave, Gautam (August 2105). "The Ancient Immunoglobulin Domains of Peroxidasin Are Required to Form Sulfilimine Cross-links in Collagen IV". The Journal of Biological Chemistry. 290 (35): 21741–21748. doi:10.1074/jbc.M115.673996. {{cite journal}}: Check date values in: |date= (help)CS1 maint: unflagged free DOI (link)
  24. ^ Obinger, Christian; et, al (February 2015). "Multidomain Human Peroxidasin 1 Is a Highly Glycosylated and Stable Homotrimeric High Spin Ferric Peroxidase". The Journal of Biological Chemistry. 290 (17): 10876–10890. doi:10.1074/jbc.M114.632273. {{cite journal}}: no-break space character in |title= at position 12 (help)CS1 maint: unflagged free DOI (link)
  25. ^ Peterfi, Zalan; Geiszt, Miklos (July 2014). "Peroxidasins: novel players in tissue genesis". Trends in Biochemical Sciences. 39 (7): 305–307. doi:10.1016/j.tibs.2014.05.005.
  26. ^ "The Skin Cancer Foundation". skincancer.org. {{cite web}}: |access-date= requires |url= (help); Check date values in: |accessdate= (help); Missing or empty |url= (help)
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Wpcrosson/sandbox&oldid=725495441"